Horiba Micros ES 60 Blood Cell Analyzer in Blood Donor Eligibility: A Validation Study.

blood component quality blood donation donor eligibility hematology analyzer quality control

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
25 Oct 2022
Historique:
received: 15 09 2022
revised: 20 10 2022
accepted: 22 10 2022
entrez: 11 11 2022
pubmed: 12 11 2022
medline: 12 11 2022
Statut: epublish

Résumé

Background: Eligibility criteria for blood donation require hemoglobin levels of ≥12.5 g/dL for women and ≥13.5 g/dL for men, and a platelet count of ≥180 × 109/L. Screening methods before donation should ensure high accuracy, precision, and ease in operation. We assessed the performance, precision, and repeatability of the Horiba Micros ES 60 (Horiba) compared to the Beckman Coulter DXH 800. Methods: Performance was compared by testing samples for each of the 11 devices across 6 sites in the Transfusion Service of Friuli Venezia Giulia Region, Italy. We measured precision by calculating the coefficient of variation (CV), concordance with ρ-Pearson’s correlation coefficient, and accuracy with F-tests. The intra-assay agreement was examined in the 11 devices, and repeatability was performed by using CV and the Kruskal−Wallis test. Results: The precision of Horiba was acceptable. Overall, ρ-Pearson’s coefficients indicated a strong correlation and positive relationship between all variables. The Bland−Altman plots showed that most of the differences lay within the limits of agreement. All CV were below the reference threshold for all the parameters. Finally, the Kruskal−Wallis test reported non-significant statistical differences for all parameters, except platelet count (p < 0.000). Conclusions: Horiba is adequate for routine pre-donation screening. The intra-assay agreement further demonstrates the accuracy of the device.

Identifiants

pubmed: 36359430
pii: diagnostics12112586
doi: 10.3390/diagnostics12112586
pmc: PMC9689173
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Blood Med. 2017 Jul 03;8:75-88
pubmed: 28740442
PLoS One. 2012;7(9):e43702
pubmed: 23028467
Transfusion. 2012 May;52(5):1031-40
pubmed: 22014071
Ann Biol Clin (Paris). 2007 Nov-Dec;65(6):671-6
pubmed: 18039614
Lancet. 2017 Nov 25;390(10110):2360-2371
pubmed: 28941948
Transfusion. 2012 Apr;52(4):702-11
pubmed: 22023513
Curr Opin Hematol. 2013 Nov;20(6):533-9
pubmed: 24104415
J Extra Corpor Technol. 2015 Jun;47(2):113-8
pubmed: 26405360
Transfusion. 2009 Sep;49(9):1971-6
pubmed: 19453988
Sci Rep. 2019 Dec 24;9(1):19770
pubmed: 31875045
Lancet. 2017 Nov 25;390(10110):2331-2333
pubmed: 28941949
Can Fam Physician. 2016 Sep;62(9):730-1
pubmed: 27629670
Thromb Res. 2006;118(2):199-204
pubmed: 16139337
Indian J Hematol Blood Transfus. 2019 Oct;35(4):736-741
pubmed: 31741630
Blood Transfus. 2009 Jul;7(3):188-92
pubmed: 19657482
Eur J Med Res. 2013 Sep 17;18:31
pubmed: 24044785

Auteurs

Silvia Tillati (S)

Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa, 56121 Pisa, Italy.

Ilaria Pati (I)

National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy.

Michela Delle Donne (M)

Transfusion Medicine Department, Udine University Hospital, 33100 Udine, Italy.

Alessandra Meneghel (A)

Transfusion Medicine Department, Udine University Hospital, 33100 Udine, Italy.

Donatella Londero (D)

Transfusion Medicine Department, Udine University Hospital, 33100 Udine, Italy.

Vincenzo De Angelis (V)

National Blood Centre, Italian National Institute of Health, 00161 Rome, Italy.

Classifications MeSH